10-KPeriod: FY2007

DEXCOM INC Annual Report, Year Ended Dec 31, 2007

Filed March 11, 2008For Securities:DXCM

Summary

DexCom, Inc. is a medical device company in the early stages of commercializing its continuous glucose monitoring (CGM) systems. The company received FDA approval for its SEVEN system in May 2007 and began commercialization in Q3 2007, with sales of this product expected to drive future revenue. Despite generating approximately $6.8 million in revenue through December 31, 2007, DexCom has incurred significant losses since inception, with an accumulated deficit of $176.3 million as of the same date. Key challenges and risks for investors include the need for broader market and physician acceptance of its products, potential manufacturing and supply chain constraints, the lack of widespread third-party reimbursement, and significant ongoing research and development expenses. The company is also facing a patent infringement lawsuit from Abbott Diabetes Care, Inc., which poses a material risk to its business. Furthermore, DexCom has a substantial debt burden with $60 million in convertible senior notes outstanding, and the potential conversion of these notes could dilute existing stockholders. While the company has a cash balance of $64.3 million as of December 31, 2007, it anticipates continued losses and may require additional funding to support its growth and product development initiatives.

Key Highlights

  • 1DexCom's SEVEN continuous glucose monitoring (CGM) system received FDA approval in May 2007 and is the primary revenue driver. Sales for the year ended December 31, 2007, were $4.6 million.
  • 2The company has a history of significant operating losses, with an accumulated deficit of $176.3 million as of December 31, 2007. Net loss for 2007 was $45.9 million.
  • 3A significant risk is the lack of broad reimbursement from third-party payors for the SEVEN system, potentially limiting widespread adoption. HCPCS codes were established in January 2008, but coverage decisions are pending.
  • 4DexCom is involved in ongoing patent litigation with Abbott Diabetes Care, Inc., which could materially impact the business and incur significant defense costs.
  • 5The company has $60 million in 4.75% Convertible Senior Notes due in 2027, which could lead to significant dilution for existing shareholders upon conversion.
  • 6Manufacturing and supply chain operations present challenges, including limited capacity and reliance on sole-source suppliers, which could constrain growth.
  • 7DexCom's ability to secure future funding is crucial, as it anticipates continued losses and significant expenses for R&D and commercialization efforts.

Frequently Asked Questions

DexCom's primary product is the SEVEN continuous glucose monitoring (CGM) system, which received FDA approval in May 2007. The company is in the early stages of commercializing this product, which is designed for up to seven days of continuous use and includes a reusable transmitter, a disposable sensor, and a handheld receiver.

DexCom has a history of significant net losses and an accumulated deficit of $176.3 million as of December 31, 2007. While revenues are growing, they are not yet sufficient to cover operating expenses, and the company anticipates continued losses in the foreseeable future. Access to capital is critical, as they may require additional funding to support operations and growth.

Key risks include: limited market acceptance and physician/patient adoption of CGM technology, manufacturing and supply chain constraints, the significant absence of broad third-party reimbursement for their products, ongoing patent litigation with Abbott Diabetes Care, potential dilution from convertible notes, and the inherent risks of operating in a highly regulated medical device industry.

DexCom has issued $60 million in 4.75% Convertible Senior Notes due in 2027. The conversion of these notes into common stock could result in significant dilution for existing shareholders, potentially affecting the stock price.